BI-1808

カスタマーレビュー

Based on 1 Customer Validation

BI-1808 is a fully human IgG1 monoclonal antibody targeting human tumor necrosis factor receptor 2 (TNFR2) (KD = 646 pM). BI-1808 inhibits Treg survival by blocking the interaction between TNFR2 and its ligand TNF-α, and via its IgG1 Fc segment binds FcγR to target and deplete intratumoral Tregs (ADCC/ADCP) and induce pro-inflammatory reprogramming of myeloid cells, ultimately activating CD8+ effector T cell-mediated tumor rejection. BI-1808 can produce synergistic antitumor effects with Pembrolizumab (HY-P9902). BI-1808 can be used for research in tumor immunity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度 : 97.75%
  • 分子量:144.206 kDa
  • 保管条件:
    Shipping with dry ice

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • 生物活性
  • 化学情報
  • プロトコル
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00